United States Biotechnology & Medical Research

Arrowhead Pharmaceuticals Inc (ARWR)

Track

Over the past 90 days, Arrowhead Pharmaceuticals Inc. has seen exclusively insider selling activity, totaling approximately $684,931.50. Key executives, including the Chief Financial Officer and Chief Medical Officer, have executed planned sales of company stock. These transactions follow the company's recent earnings report, which showed a 16.2% earnings per share beat.
Ticker: ARWR Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Arrowhead Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 12 May 2026
Value US$2,061,506.05 | Price 181.85 | Shares 89,546
Proposed sale 12 May 2026
Value US$770,172.42 | Price 322.81 | Shares 21,319
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-12 PrS Proposed sale
3.6
Hongbo Lu

Officer

Officer
89,546
181.85
US$2,061,506 		89,546 181.85 US$2,061,506
2026-05-14 2026-05-12 PlS Planned sale
3.6
Lu Hongbo
Non-Executive Director
89,019 -3.2%
171.81
US$1,855,106 		89,019 -3.2% 171.81 US$1,855,106
2026-05-12 2026-05-12 PrS Proposed sale
3.6
Hongbo Lu

Officer

Officer
21,319
322.81
US$770,172 		21,319 322.81 US$770,172
2026-05-19 2026-04-23 PrS Proposed sale
3.1
James Hamilton

Officer

Officer
10,000
75.00
US$749,998 		10,000 75.00 US$749,998
2026-04-24 2026-04-23 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
10,000 -4.2%
75.00
US$750,000 		10,000 -4.2% 75.00 US$750,000
2026-04-23 2026-04-23 PrS Proposed sale
3.1
James Hamilton

Officer

Officer
10,000
75.00
US$749,998 		10,000 75.00 US$749,998
2026-05-19 2026-04-22 PrS Proposed sale
Daniel Apel

Officer

Officer
13,095
71.34
US$934,206 		13,095 71.34 US$934,206
2026-04-24 2026-04-22 PlS Planned sale
Apel Daniel Joseph

Chief Financial Officer

Officer
8,730 -5.1%
71.92
US$627,862 		8,730 -5.1% 71.92 US$627,862
2026-04-24 2026-04-22 PlS Planned sale
Apel Daniel Joseph

Chief Financial Officer

Officer
1,157 -0.7%
70.45
US$81,511 		1,157 -0.7% 70.45 US$81,511
2026-04-24 2026-04-22 PlS Planned sale
Apel Daniel Joseph

Chief Financial Officer

Officer
3,208 -1.8%
70.11
US$224,913 		3,208 -1.8% 70.11 US$224,913
2026-04-22 2026-04-22 PrS Proposed sale
Daniel Apel

Officer

Officer
13,095
71.34
US$934,206 		13,095 71.34 US$934,206
2026-03-09 2026-03-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
10,000 -4.0%
64.19
US$641,900 		10,000 -4.0% 64.19 US$641,900
2026-03-05 2026-03-05 PrS Proposed sale
3.1
James Hamilton

Officer

Officer
10,000
64.19
US$641,870 		10,000 64.19 US$641,870
2026-01-05 2026-01-05 PrS Proposed sale
3.1
James Hamilton

Officer

Officer
40,164
63.10
US$2,534,478 		40,164 63.10 US$2,534,478
2026-01-05 2026-01-05 PrS Proposed sale
3.1
James Hamilton

Officer

Officer
39,728
63.09
US$2,506,627 		39,728 63.09 US$2,506,627
2026-01-05 2026-01-05 PrS Proposed sale
3.3
Patrick O'Brien

Officer

Officer
49,493
63.10
US$3,123,172 		49,493 63.10 US$3,123,172
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
46 -0.0%
68.00
US$3,128 		46 -0.0% 68.00 US$3,128
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
2,336 -0.5%
64.04
US$149,597 		2,336 -0.5% 64.04 US$149,597
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
5,873 -1.2%
62.91
US$369,470 		5,873 -1.2% 62.91 US$369,470
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
900 -0.2%
62.25
US$56,025 		900 -0.2% 62.25 US$56,025
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
600 -0.1%
61.12
US$36,672 		600 -0.1% 61.12 US$36,672
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
313 -0.1%
68.00
US$21,284 		313 -0.1% 68.00 US$21,284
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
900 -0.2%
66.01
US$59,409 		900 -0.2% 66.01 US$59,409
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
2,700 -0.6%
64.44
US$173,988 		2,700 -0.6% 64.44 US$173,988
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
11,842 -2.4%
63.84
US$755,993 		11,842 -2.4% 63.84 US$755,993
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
13,451 -2.6%
62.96
US$846,875 		13,451 -2.6% 62.96 US$846,875
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
6,164 -1.2%
62.23
US$383,586 		6,164 -1.2% 62.23 US$383,586
2026-01-05 2026-01-05 PlS Planned sale
3.3
O'Brien Patrick

COO

Officer
4,368 -0.8%
61.20
US$267,322 		4,368 -0.8% 61.20 US$267,322
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
309 -0.2%
68.00
US$21,012 		309 -0.2% 68.00 US$21,012
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
437 -0.3%
65.97
US$28,829 		437 -0.3% 65.97 US$28,829
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
1,200 -0.7%
64.49
US$77,388 		1,200 -0.7% 64.49 US$77,388
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
12,711 -6.8%
63.95
US$812,868 		12,711 -6.8% 63.95 US$812,868
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
14,792 -7.3%
63.01
US$932,044 		14,792 -7.3% 63.01 US$932,044
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
6,090 -2.9%
62.28
US$379,285 		6,090 -2.9% 62.28 US$379,285
2026-01-05 2026-01-05 PlS Planned sale
3.1
Hamilton James C

Chief Medical Officer

Officer
4,625 -2.2%
61.24
US$283,235 		4,625 -2.2% 61.24 US$283,235
2026-01-05 2026-01-02 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
5,771 -0.2%
66.39
US$383,137 		5,771 -0.2% 66.39 US$383,137
2026-01-05 2026-01-02 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
7,416 -0.2%
65.88
US$488,566 		7,416 -0.2% 65.88 US$488,566
2026-01-02 2026-01-02 PrS Proposed sale
2.7
Christopher Anzalone

Officer

Officer
13,187
66.10
US$871,668 		13,187 66.10 US$871,668
2025-12-30 2025-12-29 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
16,545 -0.4%
68.69
US$1,136,476 		16,545 -0.4% 68.69 US$1,136,476
2025-12-30 2025-12-29 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
35,181 -0.9%
69.33
US$2,439,099 		35,181 -0.9% 69.33 US$2,439,099
2025-12-29 2025-12-29 PrS Proposed sale
2.7
Christopher Anzalone

Officer

Officer
51,726
69.13
US$3,575,575 		51,726 69.13 US$3,575,575
2025-12-30 2025-12-26 PlS Planned sale
1.4
Ferrari Mauro
Non-Executive Director
7,530 -9.8%
70.00
US$527,100 		7,530 -9.8% 70.00 US$527,100
2025-12-29 2025-12-26 PrS Proposed sale
1.4
Mauro Ferrari

Director

Non-Executive Director
7,530
70.00
US$527,070 		7,530 70.00 US$527,070
2025-12-23 2025-12-22 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
2,574 -0.1%
68.85
US$177,220 		2,574 -0.1% 68.85 US$177,220
2025-12-23 2025-12-22 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
10,012 -0.3%
68.33
US$684,120 		10,012 -0.3% 68.33 US$684,120
2025-12-22 2025-12-22 PrS Proposed sale
2.7
Christopher Anzalone

Officer

Officer
12,586
68.43
US$861,319 		12,586 68.43 US$861,319
2025-12-23 2025-12-19 PlS Planned sale
2.2
Waddill William D.
Non-Executive Director
500 -0.9%
68.53
US$34,265 		500 -0.9% 68.53 US$34,265
2025-12-23 2025-12-19 PlS Planned sale
2.2
Waddill William D.
Non-Executive Director
5,451 -8.7%
68.01
US$370,723 		5,451 -8.7% 68.01 US$370,723
2025-12-23 2025-12-19 PlS Planned sale
2.2
Waddill William D.
Non-Executive Director
2,416 -3.7%
66.66
US$161,051 		2,416 -3.7% 66.66 US$161,051
2025-12-23 2025-12-19 PlS Planned sale
1.5
Vakiener Victoria
Non-Executive Director
1,960 -5.2%
68.39
US$134,044 		1,960 -5.2% 68.39 US$134,044
2025-12-23 2025-12-19 PlS Planned sale
1.5
Vakiener Victoria
Non-Executive Director
5,281 -12.3%
67.97
US$358,950 		5,281 -12.3% 67.97 US$358,950
2025-12-23 2025-12-19 PlS Planned sale
1.5
Vakiener Victoria
Non-Executive Director
2,799 -6.1%
66.63
US$186,497 		2,799 -6.1% 66.63 US$186,497
2025-12-23 2025-12-19 PlS Planned sale
2.6
OLUKOTUN ADEOYE Y
Non-Executive Director
827 -2.4%
68.48
US$56,633 		827 -2.4% 68.48 US$56,633
2025-12-23 2025-12-19 PlS Planned sale
2.6
OLUKOTUN ADEOYE Y
Non-Executive Director
6,083 -15.0%
68.04
US$413,887 		6,083 -15.0% 68.04 US$413,887
2025-12-23 2025-12-19 PlS Planned sale
2.6
OLUKOTUN ADEOYE Y
Non-Executive Director
3,090 -7.1%
66.70
US$206,103 		3,090 -7.1% 66.70 US$206,103
2025-12-23 2025-12-19 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
1,319 -0.0%
68.48
US$90,325 		1,319 -0.0% 68.48 US$90,325
2025-12-23 2025-12-19 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
8,147 -0.2%
68.01
US$554,077 		8,147 -0.2% 68.01 US$554,077
2025-12-23 2025-12-19 PlS Planned sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
3,979 -0.1%
66.67
US$265,280 		3,979 -0.1% 66.67 US$265,280
2025-12-19 2025-12-19 PrS Proposed sale
2.7
Christopher Anzalone

Officer

Officer
13,445
67.66
US$909,632 		13,445 67.66 US$909,632
2025-12-19 2025-12-19 PrS Proposed sale
2.2
William Waddill

Director

Non-Executive Director
8,367
67.65
US$566,001 		8,367 67.65 US$566,001
2025-12-19 2025-12-19 PrS Proposed sale
2.6
Adeoye Olukotun

Director

Non-Executive Director
10,000
67.66
US$676,589 		10,000 67.66 US$676,589
2025-12-19 2025-12-19 PrS Proposed sale
1.5
Victoria Vakiener

Director

Non-Executive Director
10,040
67.68
US$679,464 		10,040 67.68 US$679,464
2025-12-19 2025-12-17 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
1,981 -0.1%
66.30
US$131,340 		1,981 -0.1% 66.30 US$131,340
2025-12-19 2025-12-17 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
982 -0.0%
65.53
US$64,350 		982 -0.0% 65.53 US$64,350
2025-12-19 2025-12-17 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
35,750 -0.9%
64.51
US$2,306,232 		35,750 -0.9% 64.51 US$2,306,232
2025-12-19 2025-12-17 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
46,287 -1.2%
63.55
US$2,941,539 		46,287 -1.2% 63.55 US$2,941,539
2025-12-17 2025-12-17 PrS Proposed sale
2.7
Christopher Anzalone

Officer

Officer
85,000
64.04
US$5,443,253 		85,000 64.04 US$5,443,253
2025-12-16 2025-12-16 PrS Proposed sale
2.7
Christopher Anzalone

Officer

Officer
54,298
62.58
US$3,398,142 		54,298 62.58 US$3,398,142
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
3,221 -0.1%
67.87
US$218,609 		3,221 -0.1% 67.87 US$218,609
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
166 -0.0%
66.77
US$11,084 		166 -0.0% 66.77 US$11,084
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
1,300 -0.0%
65.77
US$85,501 		1,300 -0.0% 65.77 US$85,501
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
1,000 -0.0%
64.96
US$64,960 		1,000 -0.0% 64.96 US$64,960
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
6,661 -0.2%
64.29
US$428,236 		6,661 -0.2% 64.29 US$428,236
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
8,476 -0.2%
62.94
US$533,479 		8,476 -0.2% 62.94 US$533,479
2025-12-16 2025-12-16 S Sale
2.7
Anzalone Christopher Richard

Chief Executive Officer

Executive Director
14,095 -0.4%
62.12
US$875,581 		14,095 -0.4% 62.12 US$875,581
Explore more

More insider trading research around Arrowhead Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America